CRISPR-Cas9 patents: Don’t get confused!

Licence agreement

Why not?
Because there are only t​hree foundational patent portfolios!

To protect its clients from infringement risks, genOway invested substantially to hold licenses under all three portfolios.

Consequently:

  • Our customers are authorized to use CRISPR-Cas9 models for R&D (internal or commercial) with no need to acquire any additional license from any third party
  • You can acquire the authorization from genOway for the internal development or usage of rodent models from third-party providers

 

Each granted patent is represented by a colored dot.

 

The three foundational patent portfolios in the eukaryotic field are from:

  1. Sigma-Aldrich, aka Merck, which covers any CRISPR-Cas9 system for modifying a target DNA leading to a double-stranded break (this system may be associated with an exogenous sequence to perform Knockin)
  2. Berkeley, which covers any CRISPR-Cas9 system for modifying a target sequence along with at least one guide RNA
  3. Broad, which covers any CRISPR-Cas9 system for modifying a target sequence, where the CRISPR system is delivered to cells in the form of vectors

 

Contact our licensing service for more information

genOway

We will be in touch within one business day.

Send message Required fields*
 

Privacy & Confidentiality

We value your privacy. We will never give, lease, sell or otherwise disclose your personal information. Your project details will remain strictly confidential.